Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor
about
Golgi-located NTPDase1 of Leishmania major is required for lipophosphoglycan elongation and normal lesion development whereas secreted NTPDase2 is dispensable for virulenceGPI-anchored proteins and glycoconjugates segregate into lipid rafts in Kinetoplastida.Glycosphingolipid antigens of Leishmania (Leishmania) amazonensis amastigotes identified by use of a monoclonal antibodyParasite Carbohydrate Vaccines.Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccinesDevelopmental modification of lipophosphoglycan during the differentiation of Leishmania major promastigotes to an infectious stage.Leishmaniasis: current status of vaccine developmentChemical structure of Trichomonas vaginalis surface lipoglycan: a role for short galactose (β1-4/3) N-acetylglucosamine repeats in host cell interactionCharacterization of integral membrane proteins of Leishmania major by Triton X-114 fractionation and analysis of vaccination effects in miceLipophosphoglycan blocks attachment of Leishmania major amastigotes to macrophages.The Mac-2 antigen is a galactose-specific lectin that binds IgE.Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensDifferential Impact of LPG-and PG-Deficient Leishmania major Mutants on the Immune Response of Human Dendritic Cells.Down-Regulation of TLR and JAK/STAT Pathway Genes Is Associated with Diffuse Cutaneous Leishmaniasis: A Gene Expression Analysis in NK Cells from Patients Infected with Leishmania mexicanaA subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycanCarbohydrate based vaccines.Leishmania promastigotes require opsonic complement to bind to the human leukocyte integrin Mac-1 (CD11b/CD18).Leishmaniases of the New World: current concepts and implications for future researchIdentification of a macrophage-binding determinant on lipophosphoglycan from Leishmania major promastigotesStudy of Leishmania major-infected macrophages by use of lipophosphoglycan-specific monoclonal antibodiesEvidence of T-cell recognition in mice of a purified lipophosphoglycan from Leishmania majorLeishmania dihydroxyacetonephosphate acyltransferase LmDAT is important for ether lipid biosynthesis but not for the integrity of detergent resistant membranes.Carbohydrate vaccines: developing sweet solutions to sticky situations?Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Vaccine Development Against Leishmania donovani.Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein.Leishmania cell wall as a potent target for antiparasitic drugs. A focus on the glycoconjugates.Delivery systems for Leishmania vaccine development.Metabolic changes in glucose transporter-deficient Leishmania mexicana and parasite virulence.The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes.Inhibitory effects on protein kinase C activity by lipophosphoglycan fragments and glycosylphosphatidylinositol antigens of the protozoan parasite LeishmaniaCharacterization of a ricin-resistant mutant of Leishmania donovani that expresses lipophosphoglycan.Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11Identification of membrane dipeptidase as a major glycosyl-phosphatidylinositol-anchored protein of the pancreatic zymogen granule membrane, and evidence for its release by phospholipase A.Activation of human T lymphocytes by Leishmania lipophosphoglycan.A simple purification of procyclic acidic repetitive protein and demonstration of a sialylated glycosyl-phosphatidylinositol membrane anchor.Mapping of the antigenic determinants of the T. cruzi kinetoplastid membrane protein-11. Identification of a linear epitope specifically recognized by human Chagasic sera.Structural characterization of a novel glycosyl-phosphatidylinositol from the protozoan Tetrahymena mimbres.Liposomal adjuvant development for leishmaniasis vaccines.
P2860
Q28542765-0C2D43EB-B6E6-4068-846D-5D5AD29DA523Q32065261-1D453DC8-C40C-49E4-80DA-C4B1FFB97188Q33597411-596C1866-2CE4-4F7E-9350-668B82B910F2Q33785863-A42156F5-BE56-4AB5-B7BA-0F31C966BB00Q33870163-2BCAFC5C-01F1-4E3E-AEE3-352DE39F2AC8Q33938269-2BBB4D93-4866-4A70-AF3E-E3DFB4637C32Q33941719-0EF32F3A-4967-4687-AFDB-42F4BC412C96Q34013409-84F6FB45-8BE2-4AE5-B1D1-6B86E6D0A670Q35111975-E6EF2D73-7030-431B-81F4-EA41611D6B80Q35377451-D41AF414-1B14-4288-B92B-D28DFD6F93F0Q35596399-0FB10A2D-6A8B-4573-BBD5-526366588384Q35812875-7F17CBB1-E450-4D43-884F-6D184A3C4721Q35859111-F27334A0-A191-4C51-BFE5-D9256B4218C2Q35975567-E5270BC7-CCBE-4EE3-B594-2838619E5FFCQ36403849-A53A77F3-75EB-4398-992A-560EB8C459ADQ36456178-B39230BF-FAA0-4BCA-AE90-75EFD5C8FD35Q36530759-2E6FDC27-0A36-4DA9-97F5-50F4BDB6FA2EQ36640255-2688BA44-75C6-4E3B-B0FF-0D80FC3E7366Q36752141-F205407A-CFEC-48A4-A884-69643FD2D2BCQ36985810-180AA3C8-D050-45A6-A18C-C51E02F81A9FQ37005098-8BABF444-0416-4580-849B-7B23464B9559Q37393018-CE8CDBC3-D39E-4600-99C3-25BB44EE4FA0Q37426039-0A74C64E-595F-41ED-B78E-C4AE8FC93872Q37937329-2B2E5598-F6C0-4470-A83F-24CB3BDBA12AQ37965724-620C7207-5315-41F1-8229-5F74112E1C1EQ38012112-77DF8ED2-862B-45DE-B049-7A66D0279C3DQ38300404-AD2A94A7-843C-48EA-A9AD-C9B6F7161322Q38541158-69690375-D137-4A03-8987-07D6CA504E7CQ38746362-D0C8E462-78B0-4EA2-9364-6811F74162E3Q40278589-C053FE1C-5067-4DEA-A171-3B797496D089Q40847001-B913930B-A406-419A-BBFF-4A2D94EE6C36Q41265613-B45AE8DD-DCC6-4BA3-B30B-7CBEBF0FDAD0Q41619990-438B5741-6616-4BDE-886A-98FC8C8EFA5FQ41788261-E6CE4620-7FE1-480C-8AF1-E55B721F6EC8Q41822090-F6312710-8147-4CD5-AB01-85A9AE46B8CBQ41882389-A52F7ECD-4710-46CE-90D3-AAE59AA8DEE2Q42095439-3FAD07F4-A9E2-4F45-A776-FBC6D7EFD2B1Q42647252-5FF9977F-941E-4D33-B2E3-0DDEA24C44D0Q42862985-EC97F586-9D86-4599-9D52-A6DCB6953693Q47153161-1996381B-8C27-423A-A778-B6BCD5ECC39B
P2860
Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor
description
1987 nî lūn-bûn
@nan
1987 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@ast
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@en
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@nl
type
label
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@ast
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@en
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@nl
prefLabel
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@ast
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@en
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@nl
P2093
P2860
P356
P1476
Lipophosphoglycan of Leishmani ...... rophosphoinositol lipid anchor
@en
P2093
McConville MJ
Mitchell GF
P2860
P304
P356
10.1073/PNAS.84.24.8941
P407
P577
1987-12-01T00:00:00Z